KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Free Cash Flow (2016 - 2025)

Jazz Pharmaceuticals has reported Free Cash Flow over the past 16 years, most recently at -$453.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$453.5 million for Q4 2025, down 207.12% from a year ago — trailing twelve months through Dec 2025 was $497.7 million (down 64.34% YoY), and the annual figure for FY2025 was $497.7 million, down 64.34%.
  • Free Cash Flow for Q4 2025 was -$453.5 million at Jazz Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Over the last five years, Free Cash Flow for JAZZ hit a ceiling of $1.3 billion in Q3 2025 and a floor of -$755.3 million in Q2 2025.
  • Median Free Cash Flow over the past 5 years was $290.9 million (2022), compared with a mean of $249.0 million.
  • Biggest five-year swings in Free Cash Flow: surged 742.36% in 2022 and later tumbled 332.93% in 2025.
  • Jazz Pharmaceuticals' Free Cash Flow stood at $167.8 million in 2021, then skyrocketed by 98.22% to $332.6 million in 2022, then tumbled by 45.52% to $181.2 million in 2023, then soared by 133.65% to $423.4 million in 2024, then plummeted by 207.12% to -$453.5 million in 2025.
  • The last three reported values for Free Cash Flow were -$453.5 million (Q4 2025), $1.3 billion (Q3 2025), and -$755.3 million (Q2 2025) per Business Quant data.